The GLP-1 Giants Are Suing Each Other Now

Novo's general counsel, John Kuckelman, pointed to the numbers directly. Separate late-stage trials showed roughly 48 pounds of average weight loss for high-dose Zepbound and 47 pounds for high-dose Wegovy. When you line up the best against the best, the bragging rights evaporate.

Novo is calling this a "nationwide pattern of deceptive advertising" and alleging violations of the Lanham Act, the federal law that lets companies sue competitors over false or misleading commercial claims.

But Wait: Lilly Actually Has Real Data

This is where it gets complicated, and where Novo's case faces its biggest challenge.

Lilly isn't making things up out of thin air. There's a legitimate head-to-head clinical trial called SURMOUNT-5, published in the New England Journal of Medicine. It directly compared tirzepatide (the molecule in Zepbound) against semaglutide (the molecule in Wegovy) at their max obesity doses over 72 weeks.

The results weren't close. Tirzepatide patients lost 20.2% of their body weight on average; semaglutide patients lost 13.7%. That's roughly 50 pounds versus 33 pounds. About 48% of tirzepatide patients hit the 20% weight-loss threshold, compared to just 27% on semaglutide.

So what gives? The key nuance: SURMOUNT-5 compared Zepbound to the older max dose of Wegovy (2.4 mg), not the new 7.2 mg version approved this year. No head-to-head trial has ever pitted the highest approved doses of both drugs against each other. Novo's argument is that Lilly keeps citing a trial that no longer reflects the current treatment landscape, and presents it as the final word on which drug is better.

It's a bit like reviewing a restaurant based on a meal you had three years ago, then putting it on a billboard.

Why This Matters Beyond the Courtroom

This isn't just a legal spat between two rich companies. It could reshape how the entire GLP-1 market communicates with patients and doctors.

The financial stakes are enormous. Together, Novo and Lilly control what analysts estimate is a $100 billion-plus obesity drug market heading toward 2030. Lilly currently holds about 60% of the global branded GLP-1 market to Novo's roughly 40%. Last year, Lilly's Mounjaro and Zepbound combined for about $36.5 billion in sales.

But the two companies are heading in opposite directions. Lilly is guiding for $80 to $83 billion in total 2026 sales, implying around 25% growth. Novo, meanwhile, has warned of a potential 5 to 13% decline in sales and operating profit this year, squeezed by U.S. pricing pressure and international competition.

From that angle, the lawsuit looks less like righteous indignation and more like a defensive play by a company watching its market share slip away.

The Legal Precedent Is Messy

Pharma companies suing each other over ads isn't new, but it's rarely this high-profile. The Lanham Act has been used in drug marketing disputes for decades, from the 1990 Sandoz v. Richardson-Vicks case (which established that regulatory violations alone aren't enough to win) to Zeneca v. Eli Lilly in 1999, where a court issued a preliminary injunction against Lilly over claims about Evista's cancer-prevention benefits.

The Supreme Court's 2014 POM Wonderful v. Coca-Cola decision confirmed that FDA-regulated products aren't immune from false advertising suits. So Novo has a viable legal pathway. The question is whether a court will agree that Lilly's ads cross the line from aggressive-but-legal marketing into genuinely misleading territory.

What Happens Next

Novo has signaled it will seek a preliminary injunction if Lilly doesn't voluntarily pull the ads. That would force a judge to weigh in quickly on whether the campaigns should come down while the case plays out.

Wall Street, for its part, isn't panicking. Analysts are treating this as a tactical escalation in the GLP-1 duopoly, not a thesis-changing event. The general read: it raises litigation and regulatory risk around comparative advertising for both companies, and it could make future DTC campaigns more conservative.

But the bigger picture hasn't changed. Both drugs work. Both companies are printing money. And the obesity market is still growing faster than almost anything else in pharma.

The real losers here might be the ad agencies. Crafting a Zepbound commercial just got a lot harder.

Two Minutes to Decide If You Need Wegovy

Former LifeMD employees allege clinicians had just two minutes per patient to prescribe powerful GLP-1 weight-loss drugs. The STAT News investigation puts Novo Nordisk's entire telehealth strategy under a harsh spotlight.